Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. (PHIO) has reported zero cyber incidents and zero red-flag 8-K filings over the past 90 days. However, a narrow observation window shows limited signal; the full $49 Report extends analysis across 12 months of SEC filings, layering in dilution risk scoring, detailed financing history, and AI-detected regulatory patterns that shorter windows miss. The Report also contextualizes any officer changes, debt issuances, or capital raises against peer benchmarks and clinical-stage biotech norms. The full $49 Report adds comprehensive 12-month coverage with dilution risk quantification and financing trajectory analysis.